Frost & Sullivan
Growth-focused consultancy offering GPaaS
Account Manager - Subscription Sales, Global Markets
About the job
- A bachelor's degree in Business, Marketing, Economics, or a related discipline is required.
- Five to twelve years of proven experience in B2B sales, business development, consultative sales, or subscription sales is required.
- Demonstrated success in new business acquisition and hunter-led sales environments is required.
- Strong experience selling to clients in the United States and European markets is required.
- Proven experience managing the complete sales cycle from prospecting to closing is required.
- A strong existing client and prospect network across the United States and/or Europe is required.
- Experience engaging senior stakeholders and decision-makers, including C-suite executives, is required.
- A consistent track record of meeting or exceeding revenue and sales targets is required.
- Experience using customer relationship management platforms to manage pipeline, forecasting, and sales activities is required.
- Candidates must be able to work independently in a target-driven, fast-paced global environment.
- Candidates must demonstrate strength in hunter and new business development, subscription sales, end-to-end sales cycle management, consultative and solution selling, strategic account development, senior stakeholder and C-suite engagement, pipeline and forecast management, commercial negotiation, relationship management, strategic thinking, and market and industry understanding.
- Own the end-to-end sales cycle across the United States and European markets, from prospecting and lead generation through negotiation and closure.
- Identify, develop, and convert new business opportunities within target industries and accounts.
- Leverage an established client and prospect network to generate qualified opportunities and accelerate pipeline growth.
- Drive subscription sales by understanding client business challenges and positioning relevant research and advisory solutions.
- Build and maintain relationships with senior decision-makers and C-suite stakeholders across target accounts.
- Develop an understanding of client priorities, industry trends, and market dynamics to deliver a consultative sales approach.
- Conduct discovery meetings, presentations, solution discussions, commercial negotiations, and contract closures.
- Achieve and exceed revenue, subscription, pipeline, and new-logo acquisition targets.
- Develop and manage a sales pipeline across assigned geographies and industries.
- Prepare proposals, commercial presentations, and business cases tailored to client requirements.
- Collaborate with research, consulting, and delivery teams to align solutions with client objectives.
- Maintain accurate opportunity, activity, and forecast information in customer relationship management systems.
- Monitor market developments and competitor activity to identify emerging opportunities and strengthen the sales strategy.
- Contribute to account and territory strategies to support sustained revenue growth.
- An MBA is preferred.
- Prior experience selling subscription-based products, research, intelligence, advisory, consulting, software as a service, or information services is highly preferred.
- Proven success selling into the United States, Europe, and Asia-Pacific markets with an understanding of regional buying behavior is desirable.
About the company
Frost & Sullivan helps large companies pursue growth by providing Strategic Growth consulting and market research. Its core offering, Growth Pipeline as a Service (GPaaS), gives clients a structured process to identify and prioritize growth opportunities, track megatrends, and build a sustainable pathway for expansion. GPaaS works by combining market intelligence, scenario planning, and opportunity prioritization to create a pipeline of actionable growth ideas that executives can invest in. The company differentiates itself from competitors through its long history (over six decades), a disciplined, process-driven approach to uncovering and validating growth opportunities, and a focus on turning insights into a concrete growth agenda rather than just research. Frost & Sullivan’s goal is to help clients achieve transformational, sustainable growth by turning market insights into a clear, executable plan that drives economic value.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Mountain View, California
Founded
1961
Get referred to Frost & Sullivan
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sept. 9, 2026: GIL Japan 2026 targets 300 leaders, reinforcing Frost & Sullivan's executive access.
- Sept. 7, 2026: Janesh Janardhanan now owns global subscriptions P&L and expansion.
- Aug. 27, 2026: AI visibility demand creates a new consulting wedge across marketing teams.
What critics are saying
- Aug. 27, 2026: AI tools commoditize insight delivery, squeezing Frost & Sullivan's premium advisory fees.
- Glassdoor reviews updated 2026 still complain about low pay, weak management, and layoffs.
- If subscriptions stall after Janesh Janardhanan's Sept. 7, 2026 mandate, revenue concentration rises fast.
What makes Frost & Sullivan unique
- Sept. 7, 2026: Frost & Sullivan monetizes analyst intelligence through subscriptions and Growth Generator.
- Aug. 27, 2026: Optivara-powered AI Brand Equity service blends software with analyst validation.
- Over 60 years, Frost & Sullivan sells cross-industry growth strategy, not commodity market data.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Health Insurance
Company News
HDAD 2027 registration now open. Industry leaders will examine forecasts, market trends, digital transformation and aftermarket challenges at HDAD 2027. Jeff White is the Managing Editor of Counterman. He joined Babcox after a 20-year career in TV News as a Producer. You can contact him at [email protected] Published: September 11, 2026 Heavy Duty Aftermarket Dialogue, or HDAD 2027, will return for a full-day conference in Grapevine, Texas. MEMA Aftermarket Suppliers and MacKay & Company will present the event before Heavy Duty Aftermarket Week opens. The event is scheduled for January 18, 2027, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas. HDAD 2027 examines the Heavy Duty Aftermarket. HDAD 2027 will bring together industry leaders, analysts and executives to examine the state of the heavy duty aftermarket. Discussions will address what lies ahead, how the market is evolving and how suppliers can prepare. What to expect at the conference. The conference agenda will include: * Parts forecasts and the economic outlook for 2027 and beyond * Executive keynotes from a leading OEM and major fleet * Real-world analyses of aftermarket pain points and opportunities * Insights from top fleets, distributors, OEMs, dealers and supplier executives * Talk from the Top, featuring feedback from senior channel leaders * Updated industry survey findings from MEMA * MEMA's 2040 Horizon Study, presented in partnership with Frost & Sullivan * Perspectives on digital transformation, data quality and global disruption * The Fleet Panel Registration and speaker announcements. Early bird registration is available. Organizers will announce speakers at a later date. More information about the event can be found here.
Frost & Sullivan to convene more than 300 business, technology and Innovation leaders at GIL Japan 2026. 09 Sep, 2026, 22:15 IST Tokyo summit will explore how organisations can turn geopolitical risk, resource constraints and market fragmentation into competitive advantage TOKYO, Sept. 9, 2026 /PRNewswire/ - Frost & Sullivan today announced that the Growth, Innovation & Leadership Summit 2026 (GIL Global: Japan 2026) will take place on 21 October 2026 at Bellesalle Shibuya First in Tokyo. Under the theme "Strategy and Innovation to Turn Uncertainty into Competitive Advantage," the summit will bring together more than 300 senior executives, business leaders, technology specialists and innovation professionals to examine how organisations can pursue sustainable growth amid geopolitical uncertainty, resource and energy constraints, and increasing market fragmentation. Through keynote presentations, panel discussions and industry-focused sessions, GIL Japan 2026 will provide a cross-sector forum for exploring new growth opportunities, sharing practical insights and developing collaborative responses to an increasingly complex global business environment. "Business leaders are facing a convergence of geopolitical, technological and market disruption that demands both resilience and a renewed approach to innovation," said Hiroshi Yamamura, Japan Country Head at Frost & Sullivan, "GIL Japan 2026 will bring together diverse perspectives to help organisations identify emerging opportunities, make better-informed strategic decisions and turn uncertainty into a source of competitive advantage." Global outlook, innovation and industry transformation The programme will open with a keynote from Aroop Zutshi, Global President and Managing Partner at Frost & Sullivan, examining the global economic outlook and the strategic implications of operating in an increasingly uncertain environment. A cross-industry panel featuring representatives from Frost & Sullivan, Nissan Motor Corporation, Tamaki & Associates and ZenX will consider how organisations can prepare for disruption and rethink the development of new businesses. Further programme highlights will examine the growing importance of brands in the generative AI era, diversity as a competitive advantage, and the innovation capabilities required to drive the next decade of growth. Sessions will also explore emerging technologies, pharmaceutical innovation intelligence, the shift towards energy and materials infrastructure beyond EVs, and how sustainability can create value across pharmaceutical manufacturing and global food systems. The programme will feature executives and experts from Nikkei BP Consulting, Nomura Research Institute, Ltd., Chugai Pharmaceutical Co., Ltd., Yokogawa Electric Corp. and Keio University, bringing perspectives from across business, technology, healthcare, industry and academia. The summit will combine Frost & Sullivan's global market perspectives with practical insights from business, academic and industry leaders, enabling participants to consider the implications of these developments for their own growth and innovation strategies. Creating connections across industries In addition to the conference programme, GIL Japan 2026 will include an awards ceremony and a networking reception for more than 200 attendees. The in-person format is designed to encourage dialogue among participants, Frost & Sullivan experts, established corporations, ventures and start-ups - helping to create new connections and opportunities for cross-sector collaboration. The summit is intended for senior executives and professionals working across corporate strategy, business development, research and development, innovation, investment, corporate venture capital and marketing. For the latest programme information, visit the GIL Japan 2026 event website or head straight to the registration page to secure your complimentary seat here. About Frost & Sullivan Frost & Sullivan's Growth Pipeline Engine, transformational strategies and best-practice models drive the generation, evaluation, and implementation of powerful growth opportunities. Is your company prepared to survive and thrive through the coming transformation? Your Transformational Growth Journey Starts Here. Media contact Masashi Ura | 浦 昌嗣 Manager, Customer Experience Frost & Sullivan Japan Email: [email protected]
Frost & Sullivan has appointed Janesh Janardhanan as global partner and head of subscriptions. In this role, Janardhanan will lead the strategic direction, commercial growth, and global expansion of the company's analytics, subscription, and Growth Generator platforms. The appointment reflects Frost & Sullivan's continued investment in its recurring-revenue subscription offerings. These provide clients worldwide with continuous access to intelligence, growth opportunity analytics, and decision-support tools. Janardhanan brings extensive experience in commercial leadership, analytics, and growth strategy. He is a graduate of Harvard Business School and holds an MBA and a bachelor of engineering from the National University of Singapore. Under his leadership, the subscriptions business will expand its coverage, enrich its content and data assets, and strengthen its technology platforms.
Frost & Sullivan released the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector. Shanghai, China / Timesnewswire / September 3, 2026 - Frost & Sullivan, in partnership with TradeGo, LeadLeo and CCXGF (China Chengxin Green Finance Technology (Beijing) Ltd.), officially unveils the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector, delivering an in-depth panorama of the Hong-Kong 18A biotech ecosystem, capital market cycles, innovative drug R&D breakthroughs, enterprise commercialization progress and global expansion trends. The report serves as a critical reference for industry practitioners, investors, research institutions and regulatory stakeholders to grasp industrial dynamics and make strategic decisions. (To read the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector, visit https://hub.frost.com/hong-kongs-chapter-18a-biotech-sector/) Since the launch of Hong-Kong Stock Exchange's Chapter 18A listing rules in 2018, Hong Kong has built a vital financing hub for unprofitable biotech firms from Greater China. As of June 2026, nearly 93 biotech companies have gone public under the 18A framework, covering small-molecule drugs, antibody therapeutics, vaccines, nucleic-acid medicines, peptides, cell & gene therapy (CGT), IVD, surgical robots, medical devices and other high-growth innovation tracks. A growing number of enterprises have completed clinical development and achieved product commercialization, marking the sector's transition from pure R&D-driven speculation toward value-oriented industrial growth. Key Market Observations from the Blue Book 1. Biotech capital market: Cycle reset, valuation normalization, value re-pricing Global biotech capital markets have gone through distinct development phases: the upward boom from 2016-2020, a historical peak in 2021, a deep correction during 2022-2023, and the ongoing recovery from 2024 to 2026. Hong-Kong 18A stocks witnessed a heavy correction between 2021-2022 with market cap evaporating by more than 60%. Entering 2023, sectors stayed at low valuation troughs. Driven by southbound capital inflows and robust overseas BD (business development) transaction performance, the sector staged a remarkable market rebound. From mid-2024 to July 2025, the index surged over 71%, and climbed 82% across full-year 2025; market capitalization recovered to 50-60% of its 2021 peak level. Market participants are increasingly rational. Investment focus has shifted away from pure concept speculation toward clinical milestone delivery, product commercialization capacity, real-world sales performance and sustainable profitability. The industry has completed its cycle-wide shake-out, with capital firmly anchoring on fundamental business performance. 2. R&D landscape: Diversified innovation pipeline matures, multiple technological tracks blossom Chinese biotech innovation capability keeps advancing, with clinical declaration volume maintaining high activity across therapeutic segments. * Antibody therapeutics: Monoclonal antibodies remain the market cornerstone. Bispecific antibodies and ADCs act as core growth engines. From 2019 to 2025, China-origin antibody-related out-licensing (License-out) transactions jumped from 3 to 56 deals, with aggregate disclosed transaction value rocketing from USD 0.7 billion to USD 0 billion. The asset portfolio has upgraded from conventional mAbs toward high-value bispecific antibodies and ADC candidates. * Small-molecule drugs: Cutting-edge modalities including PROTAC, molecular glues and allosteric modulators gain momentum. Domestic new-drug approvals keep rising. * Vaccines: R&D spans mRNA, recombinant protein and other next-generation platforms. Domestic players accelerate product iteration and global market access. * Nucleic-acid therapeutics: Both siRNA/ASO small-nucleic-acid and mRNA drug pipelines expand rapidly. Upstream industrial-chain localisation is gathering pace. * CGT (Cell and Gene Therapy): CAR-T and other cell therapy products come to market. Advancements cover vector development, CDMO capacity build-up and diversified payment-model exploration. * Peptide medicines: GLP-1-class agents fuel market expansion, bringing new opportunities for domestic R&D and industrial translation. 3. Globalisation accelerates: License-out becomes core growth driver for Chinese biotech Cross-border BD transactions have become a signature feature of China's biotech industry. From 2021 to H1 2026, the volume of domestic biotech BD out-licensing transactions stayed at a high level. In 2025, China's biotech BD transaction value hit USD 143.14 billion. Apart from classic License-out deals, the NewCo collaboration model is gaining increasing adoption as an innovative international cooperation vehicle. Out-licensed assets are no longer limited to traditional small-molecule medicines. ADCs, bispecific antibodies, nucleic-acid drugs and other frontier innovative assets account for a larger share of deals. Chinese biotech companies are advancing multi-regional global clinical trials, registering products with FDA / EMA and steadily building worldwide commercial capabilities. 4. Technology empowerment: AI and synthetic biology reshape drug-discovery paradigms AI is penetrating the full drug-development chain, covering target identification, protein & antibody design, generative molecular optimisation, clinical-trial design. It shortens R&D cycles, cuts costs and lifts clinical success rates, evolving into a core competitive moat for biotech organisations. Synthetic biology further unlocks possibilities for the engineering of next-generation biomedicine products. 5. Evolution of 18A listed companies: From financing tool toward comprehensive global resource-integration platform 18A biotech enterprises have matured in their capital-market mindset. The listing function has upgraded from pure fundraising toward global resource integration. More firms are pushing commercial capability forward in early development phases. Operational priorities are shifting from short-term valuation management to building long-term operational strength. Capital markets are gradually forming a long-term value-driven pricing logic. The Blue Book also profiles representative 18A-listed biotech enterprises, covering vaccine, endocrine therapy, oncology innovative drug, antibody, nucleic-acid, medical device, surgical-robot and other segments, showcasing their technology platforms, R&D pipelines, key clinical milestones and commercial progress. Key Topics Covered - Overview of the Hong-Kong Chapter 18A Regime: institutional background, development history and industrial ecosystem building since 2018 - Global biotech capital-market cycles: multi-year performance of global and Hong-Kong biotech indices, market corrections, valuation troughs, and sector recovery after 2024 - HKEX 18A-listed companies: IPO issuance statistics, enterprise panorama map, track distribution, pre-IPO financing, and post-IPO secondary-market performance - In-depth analysis of core innovative-drug tracks * Monoclonal antibodies, bispecific antibodies and ADCs: pipeline landscape, commercial progress, and global-out-licensing data * Small-molecule drugs: PROTAC, molecular glues, allosteric modulators, and trends for domestic new-drug approvals * Vaccines: mRNA and recombinant-protein technology platforms, R&D pipelines and overseas-market layouts * Nucleic-acid therapeutics: small-nucleic-acid and mRNA pipelines plus upstream industrial-chain localization * Cell and Gene Therapy (CGT): R&D of CAR-T and other products, CDMO development and exploration of payment models * Peptide medicines: market growth driven by GLP-1 and domestic industrial-transformation opportunities - Cross-border business-development and globalization of Chinese biotech firms: License-out / License-in and NewCo collaboration models, transaction scales, asset structures, and advancement of global clinical programs - Technology-driven innovation: AI-empowered drug R&D and synthetic biology reshaping biopharma research paradigms - ESG development status of Hong-Kong 18A-listed biotech enterprises - Innovative medical-device tracks: high-growth segments including IVD, surgical robots and endoscopes - Representative enterprise case studies: profiles of typical 18A-listed firms covering technology platforms, pipelines, clinical milestones and commercial-status updates - Future outlook: development trends for the Hong-Kong 18A biotech sector, paths for enterprise-capability upgrading, and the capital-market's evolution toward long-value-oriented pricing About Frost & Sullivan Frost & Sullivan (the Growth Partnership Company) has supported global enterprises for more than 65 years on growth-strategy formulation. It serves Global 1,000 corporations, emerging enterprises and public-sector clients, delivering market research, industry blue-book publication, benchmark analysis and strategic consulting services across healthcare, advanced-technology, new-energy and other vertical sectors.
Frost & Sullivan released the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector. Shanghai, China / Timesnewswire / September 3, 2026 - Frost & Sullivan, in partnership with TradeGo, LeadLeo and CCXGF (China Chengxin Green Finance Technology (Beijing) Ltd.), officially unveils the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector, delivering an in-depth panorama of the Hong-Kong 18A biotech ecosystem, capital market cycles, innovative drug R&D breakthroughs, enterprise commercialization progress and global expansion trends. The report serves as a critical reference for industry practitioners, investors, research institutions and regulatory stakeholders to grasp industrial dynamics and make strategic decisions. (To read the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector, visit https://hub.frost.com/hong-kongs-chapter-18a-biotech-sector/) Since the launch of Hong-Kong Stock Exchange's Chapter 18A listing rules in 2018, Hong Kong has built a vital financing hub for unprofitable biotech firms from Greater China. As of June 2026, nearly 93 biotech companies have gone public under the 18A framework, covering small-molecule drugs, antibody therapeutics, vaccines, nucleic-acid medicines, peptides, cell & gene therapy (CGT), IVD, surgical robots, medical devices and other high-growth innovation tracks. A growing number of enterprises have completed clinical development and achieved product commercialization, marking the sector's transition from pure R&D-driven speculation toward value-oriented industrial growth. Key Market Observations from the Blue Book 1. Biotech capital market: Cycle reset, valuation normalization, value re-pricing Global biotech capital markets have gone through distinct development phases: the upward boom from 2016-2020, a historical peak in 2021, a deep correction during 2022-2023, and the ongoing recovery from 2024 to 2026. Hong-Kong 18A stocks witnessed a heavy correction between 2021-2022 with market cap evaporating by more than 60%. Entering 2023, sectors stayed at low valuation troughs. Driven by southbound capital inflows and robust overseas BD (business development) transaction performance, the sector staged a remarkable market rebound. From mid-2024 to July 2025, the index surged over 71%, and climbed 82% across full-year 2025; market capitalization recovered to 50-60% of its 2021 peak level. Market participants are increasingly rational. Investment focus has shifted away from pure concept speculation toward clinical milestone delivery, product commercialization capacity, real-world sales performance and sustainable profitability. The industry has completed its cycle-wide shake-out, with capital firmly anchoring on fundamental business performance. 2. R&D landscape: Diversified innovation pipeline matures, multiple technological tracks blossom Chinese biotech innovation capability keeps advancing, with clinical declaration volume maintaining high activity across therapeutic segments. * Antibody therapeutics: Monoclonal antibodies remain the market cornerstone. Bispecific antibodies and ADCs act as core growth engines. From 2019 to 2025, China-origin antibody-related out-licensing (License-out) transactions jumped from 3 to 56 deals, with aggregate disclosed transaction value rocketing from USD 0.7 billion to USD 0 billion. The asset portfolio has upgraded from conventional mAbs toward high-value bispecific antibodies and ADC candidates. * Small-molecule drugs: Cutting-edge modalities including PROTAC, molecular glues and allosteric modulators gain momentum. Domestic new-drug approvals keep rising. * Vaccines: R&D spans mRNA, recombinant protein and other next-generation platforms. Domestic players accelerate product iteration and global market access. * Nucleic-acid therapeutics: Both siRNA/ASO small-nucleic-acid and mRNA drug pipelines expand rapidly. Upstream industrial-chain localisation is gathering pace. * CGT (Cell and Gene Therapy): CAR-T and other cell therapy products come to market. Advancements cover vector development, CDMO capacity build-up and diversified payment-model exploration. * Peptide medicines: GLP-1-class agents fuel market expansion, bringing new opportunities for domestic R&D and industrial translation. 3. Globalisation accelerates: License-out becomes core growth driver for Chinese biotech Cross-border BD transactions have become a signature feature of China's biotech industry. From 2021 to H1 2026, the volume of domestic biotech BD out-licensing transactions stayed at a high level. In 2025, China's biotech BD transaction value hit USD 143.14 billion. Apart from classic License-out deals, the NewCo collaboration model is gaining increasing adoption as an innovative international cooperation vehicle. Out-licensed assets are no longer limited to traditional small-molecule medicines. ADCs, bispecific antibodies, nucleic-acid drugs and other frontier innovative assets account for a larger share of deals. Chinese biotech companies are advancing multi-regional global clinical trials, registering products with FDA / EMA and steadily building worldwide commercial capabilities. 4. Technology empowerment: AI and synthetic biology reshape drug-discovery paradigms AI is penetrating the full drug-development chain, covering target identification, protein & antibody design, generative molecular optimisation, clinical-trial design. It shortens R&D cycles, cuts costs and lifts clinical success rates, evolving into a core competitive moat for biotech organisations. Synthetic biology further unlocks possibilities for the engineering of next-generation biomedicine products. 5. Evolution of 18A listed companies: From financing tool toward comprehensive global resource-integration platform 18A biotech enterprises have matured in their capital-market mindset. The listing function has upgraded from pure fundraising toward global resource integration. More firms are pushing commercial capability forward in early development phases. Operational priorities are shifting from short-term valuation management to building long-term operational strength. Capital markets are gradually forming a long-term value-driven pricing logic. The Blue Book also profiles representative 18A-listed biotech enterprises, covering vaccine, endocrine therapy, oncology innovative drug, antibody, nucleic-acid, medical device, surgical-robot and other segments, showcasing their technology platforms, R&D pipelines, key clinical milestones and commercial progress. Key Topics Covered - Overview of the Hong-Kong Chapter 18A Regime: institutional background, development history and industrial ecosystem building since 2018 - Global biotech capital-market cycles: multi-year performance of global and Hong-Kong biotech indices, market corrections, valuation troughs, and sector recovery after 2024 - HKEX 18A-listed companies: IPO issuance statistics, enterprise panorama map, track distribution, pre-IPO financing, and post-IPO secondary-market performance - In-depth analysis of core innovative-drug tracks * Monoclonal antibodies, bispecific antibodies and ADCs: pipeline landscape, commercial progress, and global-out-licensing data * Small-molecule drugs: PROTAC, molecular glues, allosteric modulators, and trends for domestic new-drug approvals * Vaccines: mRNA and recombinant-protein technology platforms, R&D pipelines and overseas-market layouts * Nucleic-acid therapeutics: small-nucleic-acid and mRNA pipelines plus upstream industrial-chain localization * Cell and Gene Therapy (CGT): R&D of CAR-T and other products, CDMO development and exploration of payment models * Peptide medicines: market growth driven by GLP-1 and domestic industrial-transformation opportunities - Cross-border business-development and globalization of Chinese biotech firms: License-out / License-in and NewCo collaboration models, transaction scales, asset structures, and advancement of global clinical programs - Technology-driven innovation: AI-empowered drug R&D and synthetic biology reshaping biopharma research paradigms - ESG development status of Hong-Kong 18A-listed biotech enterprises - Innovative medical-device tracks: high-growth segments including IVD, surgical robots and endoscopes - Representative enterprise case studies: profiles of typical 18A-listed firms covering technology platforms, pipelines, clinical milestones and commercial-status updates - Future outlook: development trends for the Hong-Kong 18A biotech sector, paths for enterprise-capability upgrading, and the capital-market's evolution toward long-value-oriented pricing About Frost & Sullivan Frost & Sullivan (the Growth Partnership Company) has supported global enterprises for more than 65 years on growth-strategy formulation. It serves Global 1,000 corporations, emerging enterprises and public-sector clients, delivering market research, industry blue-book publication, benchmark analysis and strategic consulting services across healthcare, advanced-technology, new-energy and other vertical sectors.